Top-News

Astellas Pharma ADR News

Aktie
WKN:  A0YGQP ISIN:  US04623U1025 US-Symbol:  ALPMY
10,05 $
+0,08 $
+0,80%
03.05.24 21:53:53
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
22,52 Mrd. €
Streubesitz
-
Faktor
4
Originalaktie
JP3942400007
Index-Zugehörigkeit
-
IR-Website
zur Website

Astellas Pharma ADR News

15.12.23 - PR Newswire
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
PADCEV® (enfortumab vedotin-​ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer PR Newswire
12.12.23 - PR Newswire
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics PR Newswire
10.12.23 - PR Newswire
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause PR Newswire
30.11.23 - PR Newswire
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-​ejfv) with KEYTRUDA® (pembrolizumab) for First-​Line ...
29.11.23 - PR Newswire
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy PR Newswire
16.11.23 - PR Newswire
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting PR Newswire
16.11.23 - PR Newswire
University of Tsukuba and Astellas Confirm a Strategic Partnership
University of Tsukuba and Astellas Confirm a Strategic Partnership PR Newswire
15.11.23 - PR Newswire
Astellas to Acquire Propella Therapeutics
Astellas to Acquire Propella Therapeutics PR Newswire
15.11.23 - PR Newswire
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology PR Newswire
04.11.23 - PR Newswire
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years PR Newswire
22.10.23 - PR Newswire
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-​Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-​ejfv) and KEYTRUDA® ...
15.10.23 - PR Newswire
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Astellas to Share New Data Across Hard-​to-Treat Cancers During ESMO Congress 2023 PR Newswire
13.10.23 - PR Newswire
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) PR Newswire
10.10.23 - PR Newswire
Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan
Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-​no-ha, Japan PR Newswire
22.09.23 - PR Newswire
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
PADCEV® (enfortumab vedotin-​ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-​Free Survival in Patients With Previously Untreated ...
20.09.23 - PR Newswire
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
Two-time Emmy® Award-​Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA) PR Newswire
18.09.23 - PR Newswire
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire
18.09.23 - PR Newswire
Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize
Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize PR Newswire
18.09.23 - PR Newswire
Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society
Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society PR Newswire
14.09.23 - PR Newswire
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland
Astellas to Invest more than €330 Million in a New State-​of-the-Art Facility in Tralee, Co. Kerry. Ireland PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »